<DOC>
	<DOCNO>NCT00954447</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability linagliptin ( 5 mg / daily ) compare Placebo long term treatment ( 52 week longer ) combination basal insulin patient type 2 diabetes mellitus insufficient glycaemic control .</brief_summary>
	<brief_title>Efficacy Safety Linagliptin Combination With Insulin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diabetes type 2 , detectable Cpeptide , HbA1c 710 % 2 . Pretreatment basal insulin +/ Metformin or/and +/ Pioglitazone 3 Age &gt; 18 year , BMI &lt; = 45 kg/m2 Exclusion criterion : 1 . Uncontrolled hyperglycemia Runin 2 . Myocardial infarction , stroke TIA within 3 month prior inform consent 3 . Liver impairment ; gastric surgery ; medical history cancer last 5 year 4 . Other antidiabetic drug , antiobesity drug , systemic steroid , investigational drug randomisation 5 . Unsufficient birth control , pregnancy nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>